Wirsching, H., Tabatabai, G., Roelcke, U., Hottinger, A., Jörger, F., Schmid, A., . . . Weller, M. (2018). Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: The randomized, open-label, phase II ARTE trial. Annals of Oncology, 29(6), 1423-1430. https://doi.org/10.1093/annonc/mdy120

Wirsching, H.-G, et al. "Bevacizumab Plus Hypofractionated Radiotherapy Versus Radiotherapy Alone in Elderly Patients with Glioblastoma: The Randomized, Open-label, Phase II ARTE Trial." Annals of Oncology 29, no. 6 (2018): 1423-1430. https://doi.org/10.1093/annonc/mdy120.

Wirsching, H.-G, et al. "Bevacizumab Plus Hypofractionated Radiotherapy Versus Radiotherapy Alone in Elderly Patients with Glioblastoma: The Randomized, Open-label, Phase II ARTE Trial." Annals of Oncology, vol. 29, no. 6, 2018, pp. 1423-1430, https://doi.org/10.1093/annonc/mdy120.